Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Latanoprost and NB-UVB in Non-segmental Vitiligo
NCT04811326Phase 4Unknown
- Start
- Jan 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of latanoprost ophthalmic solution 0.005% (TearClear TC-002) in Vitiligo (4 arms). Primary endpoint: Serum TWEAK Level at 3 months. Status: unknown.
02
Drugs
latanoprost ophthalmic solution 0.005% (TearClear TC-002)
03
Conditions
Vitiligo
Beyond the preview
Go deeper on NCT04811326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811326.